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Abstract
Background: Tenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 infection but has
no published data regarding pre-clinical testing using in vitro and ex vivo models. To validate our findings with on-going
clinical trial results, we evaluated topical tenofovir gel for safety and efficacy. We also modeled systemic application of
tenofovir for efficacy.
Methods and Findings: Formulation assessment of tenofovir gel included osmolality, viscosity, in vitro release, and
permeability testing. Safety was evaluated by measuring the effect on the viability of vaginal flora, PBMCs, epithelial cells, and
ectocervical and colorectal explant tissues. For efficacy testing, PBMCs were cultured with tenofovir or vehicle control gels and
HIV-1 representing subtypes A, B, and C. Additionally, polarized ectocervical and colorectal explant cultures were treated
apically with either gel. Tenofovir was added basolaterally to simulate systemic application. All tissues were challenged with
HIV-1 applied apically. Infection was assessed by measuring p24 by ELISA on collected supernatants and immunohisto-
chemistry for ectocervical explants. Formulation testing showed the tenofovir and vehicle control gels were .10 times
isosmolar. Permeability through ectocervical tissue was variable but in all cases the receptor compartment drug concentration
reached levels that inhibit HIV-1 infection in vitro. The gels were non-toxic toward vaginal flora, PBMCs, or epithelial cells. A
transient reduction in epithelial monolayer integrity and epithelial fracture for ectocervical and colorectal explants was noted
and likely due to the hyperosmolar nature of the formulation. Tenofovir gel prevented HIV-1 infection of PBMCs regardless of
HIV-1 subtype. Topical and systemic tenofovir were effective at preventing HIV-1 infection of explant cultures.
Conclusions: These studies provide a mechanism for pre-clinical prediction of safety and efficacy of formulated
microbicides. Tenofovir was effective against HIV-1 infection in our algorithm. These data support the use of tenofovir for
pre-exposure prophylaxis.
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Introduction
The recent report from the Joint United Nations Programme on
HIV/AIDS (UNAIDS) suggests the HIV-1 epidemic has stabilized
[1]. Despite this encouraging news, this past year, 2.7 million new
infections and 2 million more people have perished as a
consequence of HIV-1 infection. A renewed effort in the HIV-1
prevention field has taken place over the past decade. As the
majority of new infections occur through sexual intercourse, new
approaches in addition to vaccine development have been pursued
and include male circumcision, treatment of sexually transmitted
infections, and pre-exposure prophylaxis (PrEP). All have had
varying degrees of success [2,3,4,5].
Sub-Saharan Africa encompasses the majority of the global
HIV-1 infected population [1]. Women now account for
approximately half of the infected overall population and greater
than 60% in sub-Saharan Africa. A major gap in prevention
strategies is the empowerment of the receptive sexual partner with
the means to prevent HIV-1 acquisition that do not depend on
their partners’ consent. This is especially important where the
receptive partner may have difficulty negotiating the use of
condoms [6,7,8]. One of the most promising concepts is
microbicides which are products used topically, either vaginally
or rectally, or taken orally to prevent the transmission of HIV-1.
Microbicides are a form of PrEP and have the potential to be used
without the partner’s knowledge.
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9310While there are several broad classes of microbicides, three major
ones are described. One class of microbicides bolsters the natural
physiological conditions of the vagina by providing a pH buffer (e.g.
BufferGel and ACIDFORM) [9,10]. A low pH like the vaginal
environment inactivates both HIV-1 and HSV-2; the neutral pH of
the rectum may limit the utility of this product. A clinical efficacy
study was just completed and the results showed that BufferGel was
quite safe and acceptable, but not effective at preventing HIV-1
acquisition [11]. A second class of microbicides blocks the fusion of
HIV-1 with its target cells and is a large group with diverse
structures; examples include cellulose sulfate, Carraguard, and
PRO 2000. All three of these products have been evaluated in
efficacy trialswheretheprimaryendpointwasHIV-1infection.The
cellulose sulfate trials were halted early for futility or a suggestion of
harm [12,13]. The Carraguard trial demonstrated the product was
safe and acceptable by the women using it, but not effective at
preventing HIV-1 infection [14]. Of the two trials evaluating PRO
2000, the MDP301 trial had one of the two testing arms stopped
due to futility (2% PRO 2000) while the other arm (0.5% PRO
2000) completed testing. The HPTN 035 trial demonstrated that
0.5% PRO 2000 was 30% effective in preventing HIV-1 infection
[11]. The 0.5% PRO 2000 result was not statistically significant and
was confirmed by the recently completed MDP301 trial [15].
A third class of microbicides interferes with the life cycle of
HIV-1 and includes drugs that are currently used for treatment
(e.g. tenofovir) or have been evaluated for treatment (e.g. UC781
and Dapivirine). Tenofovir, a nucleotide analog HIV-1 reverse
transcriptase inhibitor, is the most extensively studied. Currently,
tenofovir is given orally in the form of the prodrug tenofovir
disoproxil fumarate (TDF) which is effective against a range of
HIV-1 subtypes as well as CCR5-using and CXCR4-using HIV-1
and is being proposed for use in PrEP clinical trials [16]. In
addition to the oral dosage form, a vaginal gel product has been
developed which contains 1% of the non-prodrug form, tenofovir.
The formulated topical gel (tenofovir gel) has been tested in non-
human primate models for pre- and post-exposure prophylaxis
with varying degrees of success [17,18] and two human safety trials
with favorable results [19,20].
The overall goal of this work was to evaluate the tenofovir gel
formulation for safety and efficacy using our pre-clinical testing
algorithm. We have a comprehensive approach for analyzing the
physical attributes of the formulation (viscosity, osmolality, in vitro
release, tissue permeability), testing for safety (genital tract flora,
epithelial cells, and ectocervical and colorectal tissue explants), and
demonstrating efficacy (prevention of HIV-1 infection in periph-
eral blood mononuclear cells [PBMCs] and ectocervical and
colorectal explants) (Figure 1). The ability to model systemically
available drugs, specifically tenofovir, against mucosal HIV-1
infection using ex vivo assays has not been previously accomplished.
Therefore, our second goal was to determine whether systemically
available tenofovir could be modeled ex vivo for efficacy. While our
data show that the topical tenofovir gel formulation was
hyperosmolar which was reflected in changes in epithelial
monolayer integrity and explant epithelium fracture, it was safe
for normal vaginal flora and effective in the PBMCs and explant
cultures against HIV-1 challenge. Moreover, systemic administra-
tion of tenofovir was also effective at preventing HIV-1 infection of
the ectocervical and colorectal explant cultures. Collectively, these
data suggest that tenofovir is an excellent candidate as a topical
vaginal or rectal microbicide and for oral PrEP. Our intent is to
validate our pre-clinical algorithm with the findings from the on-
going tenofovir gel and PrEP efficacy trials. Rigorous evaluation of
formulated products prior to inclusion in large efficacy studies
should be done to ensure successful outcomes.
Materials and Methods
Products
Tenofovir gel also known as 9-[2-(phosphonomethoxy)propy-
l]adenine (PMPA) gel, vehicle control gel, and tenofovir powder
were provided by Gilead Sciences, Inc. (Foster City, CA) and
CONRAD (Arlington, VA). Tenofovir gel is composed of 1%
tenofovir incorporated into a formulation containing a gelling
agent (hydroxyethycellulose), glycerin, EDTA, citric acid, and the
preservatives methyl and propyl parabens. The vehicle control gel
was the same formulation but without the active ingredient,
tenofovir. While tenofovir disoproxil fumarate is the oral prodrug
of tenofovir, it was not provided or used for this work. A 10 mg/ml
solution of the tenofovir powder was prepared as described below.
Where appropriate, Gynol II (Ortho-McNeil-Janssen Pharmaceu-
tical, Inc. Titusville, NJ) an over-the-counter 3% nonoxynol 9 (N9)
gel was used as a positive control for cell and tissue toxicity.
Human Tissue
Normal human ectocervical (IRB # 0503103) and colorectal
(IRB # 0602024) tissues were acquired from pre-menopausal
women undergoing hysterectomy or persons undergoing colorectal
surgery for non-inflammatory conditions, respectively. All tissue
was obtained through IRB approved protocols at the University of
Pittsburgh. The IRB deemed this exempt because surgical tissue
remainders that would otherwise be discarded are used for this
research. No patient identifiers are provided and all tissues are
collected through an Honest Broker de-linking patient ID to the
investigators. When the patients consent for surgery, they sign a
general consent that their tissue remainders can be used for
research; therefore, a study specific consent form was not deemed
necessary.
Physicochemical Testing
The major physicochemical parameters typically evaluated for
semi-solids include viscosity, osmolality, pH, and in vitro drug
release. Likewise, permeability of the drug through tissue barriers
Figure 1. Microbicide pre-clinical testing algorithm. Tenofovir
and vehicle control gels were evaluated through a comprehensive pre-
clinical algorithm. The algorithm focuses on testing the formulation’s
physiochemical properties and the ability to release the drug; in vitro
testing that includes safety of vaginal flora, epithelial and immune cells,
and efficacy against multiple HIV-1 clades; and ex vivo testing using
ectocervical and colorectal explants to evaluate drug absorption and
formulation safety and efficacy against HIV-1. The data obtained from
this algorithm along with data supplied by the manufacturer aid in the
decision to continue testing the product.
doi:10.1371/journal.pone.0009310.g001
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whether the drug has the capacity to reach target cells or become
systemically available.
Viscosity was determined using the CP41 spindle on a cone/
plate Brookfield Model DVIII viscometer (Brookfield Eng. Lab.,
Inc., Middleboro, MA). Data was collected using Rheocalc
software (Brookfield Eng. Lab., Inc.). The sample was placed in
the sample cup of the instrument and allowed to equilibrate to
37uC for 10 min. Viscosity was measured using a program where
shear rate was increased from 0.2 to 60.0 sec
21 and subsequently
decreased to 0.2 sec
21. To compare data across samples, viscosity
values acquired at 60 sec
21 were used in the analysis. Yield stress
was calculated by Rheocalc Software using the Bingham equation
which gave the best fit.
pH was determined using an Accumet AR20 pH meter (Fisher)
with an AccuFet (Fisher) semisolid-state probe calibrated using two
points, pH 4.0 and 7.0.
Osmolality was determined using a Vapor Pressure 5520
Osmometer (Wescor, Inc., Logan, UT) calibrated with Opti-mole
290 and 1000 mmol/kg osmolality standards.
In vitro release studies were carried out using the Hanson
MicroetteH system. Spectra/Por membrane discs (Spectrum
Chemical Mfg. Corp., New Brunswick, NJ) were used as the inert
membrane and preconditioned with a 1 mM EDTA (Spectrum
Chemical Mfg. Corp.) solution, the receptor medium was
phosphate buffered saline. The membrane was placed on the
Hanson MicroetteH system with a premeasured amount of
tenofovir gel. Samples were taken from the receptor compartment
at predetermined time intervals and assayed for tenofovir content
using high pressure liquid chromatography methods.
Permeability studies (drug moving from the gel through tissue
barriers) were conducted in a Franz diffusion cell. The Franz cell is
a two-compartment system consisting of an upper chamber (donor
compartment) and a lower chamber (receiver compartment). The
Franz cells were water-jacketed and temperature was maintained
at 37uC throughout the experiment via a circulating water bath.
DMEM (Dulbecco’s Modification of Eagle’s Medium, Mediatech,
Manassas, VA) was used in the receiver chamber. The receiver
chamber was continuously stirred by magnetic stir bar. The
volume of the receptor chamber was 4.8 mL. Ectocervical tissue
was used within 2 h of surgery and placed in a Franz diffusion cell
separating the donor compartment from the receptor compart-
ment. The epithelial side of the tissue was oriented toward the
donor compartment. The tissue was placed on the top of a 7 mm
Franz cell opening; which provided a diffusion area of 0.385 cm
2.
The tissue was equilibrated with DMEM in the donor compart-
ment for 5 min prior to the permeability study. After the
equilibration period, the DMEM solution was removed from the
donor compartment and replaced with 450 mL of tenofovir
product. Fifty mL was removed from the donor compartment for
time zero HPLC quantitation for tenofovir. Samples were
obtained from the receiver compartment at predetermined time
intervals for a total period of 6 h and fresh medium was replaced
to maintain sink conditions. Samples were assayed for tenofovir
using high pressure liquid chromatography methods.
Safety Testing
Safety encompassed normal vaginal flora, epithelial cell lines,
PBMCs, and ectocervical and colorectal explant cultures. Viability
of the bacteria, cells, and explants was measured after exposure to
the tenofovir and vehicle control gels. Additionally, epithelial
monolayer integrity as measured by transepithelial resistance
(TER) was tested.
Normal vaginal flora testing. One reference strain for each
species was obtained from the American Type Culture Collection
(Manassas, VA.). Field isolates for each species were obtained from
human vaginal samples and identified to the species level using
Gonchek IIH for N. gonorrhoeae (PML Microbiologicals) and
confirmed using the Strand Displace Assay as previously
described [21]. Lactobacillus species were identified using colony
morphology, Gram-stain reaction and catalase production and
confirmed using DNA-DNA hybridization to DNA from reference
strains [22]. The species analyzed included L. crispatus (8 strains), L.
jensenii (11 strains), L. iners (10 strains), and L. vaginalis (10 strains). L.
vaginalis strains were further classified by sequencing 16s and 23s
ribosomal RNA. Organisms were stored at 280uC in litmus milk
until needed. Stock cultures were revived by plating onto either
blood agar plates (Columbia blood agar base, PML
Microbiologicals, Wilsonville, OR) for Lactobacillus or Chocolate
agar (PML Microbiologicals or prepared in-house) for Neisseria
gonorrhoeae. Prevotella bivia and P. melaninogenica were isolated and
cultured as described previously [23].
Minimum cidal concentrations, the drug concentration required
to reduce the viability of a culture by 99.99%, were determined as
previously described [24,25]. Briefly, bacterial suspensions were
prepared by selecting isolated colonies from fresh overnight culture
plates and suspending the test organisms in saline to a density of a
0.5 McFarland standard. Suspensions were diluted in sterile saline
and then further diluted in 0.5 mM ACES buffer pH 7.0. After
incubation at 35uC for 30 min, samples were plated on to the
appropriate medium, allowed to absorb for 10 to 15 min, and then
spread over the surface of the agar plate. Plates were incubated as
described above for 24 h and evaluated for killing of the test
microorganisms by examination. Samples yielding 10 or fewer
colony forming units (representing a 99.99% kill) were considered
sensitive to killing. All results were compared to the control which
was identical but lacking tenofovir. Tenofovir powder was
suspended in ACES buffer to 10 mg/ml and was filter sterilized.
The tenofovir solution was tested as described above.
Epithelial cell lines and PBMCs testing. Epithelial cell
lines were obtained from the American Type Culture Collection
(Manassas, VA). Unless otherwise stated, culture reagents were
purchased from Hyclone (Logan, UT). Caco-2 cells, a colorectal
epithelial cell line [26], were grown in MEM alpha modified
medium supplemented with 20% heat-inactivated fetal bovine
serum (FBS; Gemini Bio-products, West Sacramento, CA),
100 mg/ml streptomycin, 100 U/ml penicillin, and 100 mM L-
glutamine. HEC-1-A cells, an endometrial epithelial cell line [27],
were grown in McCoy’s 5A medium supplemented with 10% FBS,
100 mg/ml streptomycin, 100 U/ml penicillin, and 100 mM L-
glutamine. Normal human PBMCs (Central Blood Bank,
Pittsburgh, PA) were obtained by leukophoresis from HIV-1-
negative blood donors, purified by differential centrifugation, and
stored in the gas phase of liquid nitrogen until needed. PBMCs
were grown in RPMI-1640 (cRPMI) supplemented with 10% FBS,
100 mg/ml streptomycin, 100 U/ml penicillin, and 100 mM L-
glutamine. For activation, PBMCs were stimulated for 3 days at
37uC/5% CO2 in cRPMI medium supplemented with 10%
interleukin-2 (Roche Applied Sciences, Indianapolis, IN) and
5 mg/ml phytohemagglutinin-P (Sigma Chemical Co. St. Louis,
MO).
For viability testing, dilutions were made of tenofovir and
vehicle control gels in the appropriate cell culture medium to test
for cell viability. Dilutions used included 1:5 (2 mg/ml), 1:10
(1 mg/ml), 1:20 (500 mg/ml), 1:25 (400 mg/ml), 1:40 (250 mg/ml),
1:50 (200 mg/ml), and 1:100 (100 mg/ml). For cell viability, Caco-
2 or HEC-1-A cell lines or PBMCs were plated in triplicate in a
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control gels were added to the appropriate wells. Control wells
with no treatment (cells only) and medium only were included for
background luminescence. The plate was cultured for 24 h and
then was washed twice with Hank’s Balance Salt Solution (Ca++/
Mg++-free) (HBSS). After the last wash, CellTiter-Glo
TM
(Promega Corp., Madison, WI) was added to all the wells per
the manufacturer’s instructions and luminescence was measured
using a Beckman DTX 880 plate reader. Viability was determined
based on deviations from the cell only control and presented as %
viability of control 6 standard deviation.
Additional 5 day viability testing was done with the epithelial
cell lines using the nontoxic concentrations of tenofovir and
vehicle control gels. Appropriate wells were exposed for 2 h a day
for 5 days. Control wells with no treatment (cells only) and
medium only were included for background luminescence. On day
5, the wells were washed and viability was measured as described
[28].
To determine the effect of tenofovir and vehicle control gels on
epithelial integrity, the transepithelial resistance (TER) was
measured as described previously [28]. HEC-1-A or Caco-2 cells
were grown on transwell supports until confluency was reached
and a polarized monolayer developed as measured by a MilliCell-
ERS resistance system (Millipore, Billerica, MA). At that time, a
nontoxic concentration (1:10 or 1 mg/ml) of products were added
to the apical surface of the monolayer and resistance readings were
measured as indicated. As controls, wells with cells alone, cells
treated with N9, or no cells were used. The epithelial resistance
was expressed as (V xc m
2) of the treated wells - (V xc m
2) of the no
cell wells.
Explant culture testing. Normal human ectocervical and
colorectal tissues were used. Polarized explant cultures were set-up
as previously described [29,30]. Briefly, the explant was placed
with the luminal side up in a transwell. The edges around the
explant were sealed with Matrigel
TM (BD Biosciences, San Jose,
CA). The explants were maintained with the luminal surface at the
air-liquid interface. The lamina propria was immersed in medium
for ectocervical explants or resting on medium-soaked gelfoam for
colorectal explants. Cultures were maintained at 37uCi na5 %
CO2 atmosphere.
The explants were prepared on day of surgery in duplicate. To
ensure even spread of the gels and to allow it to be mixed with
HIV-1 for the efficacy testing (below), a 1:5 dilution of tenofovir or
vehicle control gels was applied to the apical side of the explants
for 18 h. As controls, explants were untreated or a 1:5 dilution of
3% N9 gel was applied apically. The next day, explants were
washed and viability was evaluated using the MTT [1-(4,5-
dimethylthiazol-2-yl)-3,5-diphenylformazan] assay and histology
[29,30].
Efficacy Testing
To determine ability to prevent HIV-1 infection, PBMCs and
tissue explant cultures were treated apically with tenofovir gel. To
simulate systemic dosing, 1 mg/ml of tenofovir was added to the
basolateral side of the tissue explant cultures.
PBMC testing. PBMCs (10
6 cells/well) were incubated in
medium containing HIV-1 (100 TCID50/well) and a 1:20 dilution
(0.5 mg/ml) of tenofovir or vehicle control gels, or medium alone
(control) for 4 h. The PBMCs were washed 36 with HBSS and
cultured in medium at 10
6 cells/ml/well in triplicate in 48-well
plates for 14 days. Culture supernatants were collected every 3 to 4
days and replaced with fresh medium. The supernatants were
stored at 280uC until they were assayed for HIV-1 using an HIV-
1 p24gag protein ELISA (Perkin Elmer Life and Analytical
Sciences, Inc., Waltham, MA). The isolates used included HIV-
1BaL purchased from Advanced Biotechnologies, Inc. (Columbia,
MD), and primary isolates [HIV-1C959 (CCR5), HIV-1C012
(CCR5), and HIV-1A103 (CXCR4/CCR5)] obtained from the
NIH AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH.
Explant culture testing. The explants were assembled as
described above. To determine the effect of tenofovir gel on HIV-
1 infection, a 1:5 dilution of tenofovir or vehicle control gel was
mixed with HIV-1BaL and added to the apical side of the explants.
For the systemic application, 1 mg/ml of tenofovir was added to
the basolateral compartment and HIV-1BaL was added 15 min
later to the apical side of the explants. Eighteen hours after either
application the explants were washed and fresh medium (without
drug) was added to the basolateral compartment. Every 3 to 4 days
over a 3 week period, supernatant was collected and stored at -
80uC for HIV-1 p24gag analysis and fresh medium (without drug)
was replenished. Immunohistochemistry (IHC) was performed
only on ectocervical tissue for HIV-1 infected cells by staining for
p24gag [30].
To determine if either formulated or unformulated tenofovir
could prevent post-HIV-1 infection, HIV-1BaL was added to the
apical side of the ectocervical or colorectal explant cultures. Fifteen
or 60 min later, a 1:5 dilution of tenofovir gel (or vehicle control
gel) was added to the apical side of the explants or tenofovir
(1 mg/ml) in medium was added to the basolateral side of the
explants and allowed to culture for an additional 17 h. The tissues
were washed and followed as described above.
Statistical Analysis
All statistical analyses were performed using SAS version 9.1.3
on SunOS 5.9 platform.
To model the relationship between the in vitro released amount
of drug and the square root of release time, the lack-of-fit test,
using the F statistic, was used to assess the linear relationship
versus quadratic relationship. Because the linear relationship
provides a better fit to the data, a simple linear regression model
was used to estimate the drug release rate.
For tenofovir gel safety testing, epithelial cell lines, PBMCs, and
explant tissue treated with tenofovir gel or vehicle control gel were
compared to controls (no treatment group) for viability using the
one-sided nonparametric Wilcoxon Sign Rank test.
The epithelial monolayer integrity (TER) between diluted
tenofovir (1:10), vehicle control (1:10), N9 (1:150), and controls
was compared using a one-way analysis of variance. Multiple
comparisons between various drug groups versus control were
adjusted using the Dunnett’s procedure.
To evaluate the efficacy of tenofovir gel in PBMCs against HIV-
1 subtypes, comparisons of log10 transformed p24gag levels with
vehicle control gel or controls (HIV-1 only) were performed at the
peak replication time-points. To evaluate the efficacy of tenofovir
gel, vehicle control gel, or tenofovir in ectocervical and colorectal
explant cultures, comparisons of log10 transformed p24gag levels
with controls (HIV-1 only) were performed at time-points with
peak median p24 gag level for control (HIV-1 only) group. One-
sided nonparametric Wilcoxon sign rank test was conducted to
assess the efficacy difference.
Results
Tenofovir Gel Formulation Evaluation
It is required that formulations be tested to predict how the
product will function when applied to the mucosal surface. The
major physicochemical properties typically evaluated for semi-
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Osmolality is measured to understand how the drug product
deviates from normal isosmolar (290 mmol/kg) conditions. This is
important because hyperosmolar products can cause mucosal
tissue damage [31]. Tenofovir gel and its vehicle control gel had
osmolality values which were 11.5-fold (3347 mmol/kg) and 11-
fold (3189 mmol/kg), respectively, greater than isosmolar condi-
tions. Both gels were formulated at pH 4.4 which is similar to the
vaginal environment. The pH was re-tested after a 1:5 dilution in
cell culture medium and both gels had a pH of 6.4
The viscosities of the tenofovir and vehicle control gels
measured at a shear rate of 30 revolutions per minute (rpm) were
2736 centipoise (cps) and 2879 cps, respectively. These results
were reproducible in duplicate trials. Both gels were shear thinning
in nature, in that the viscosities decreased as applied shear stress
increased. The viscosities of tenofovir and vehicle control gels were
comparable to over-the-counter lubricant products KY Jelly (2765
cps) and Astroglide Gel (2071 cps).
For efficacy to be achieved from a dosage form, it is imperative
that the drug be released from the product in an efficient and
reproducible manner. The in vitro release rate reflects how the
semi-solid formulation functionally delivers tenofovir from the
dosage form. In vitro release studies were conducted to determine
the release profile of tenofovir from the gel product. In these
studies a fairly linear and reproducible release profile was obtained
for the gel product (Figure 2). The release rate of tenofovir from
the gel product formulation used in these studies was found to be
66.65 mg/cm
2/min
1/2.
The potential for systemic uptake of tenofovir when delivered
topically is assessed through permeability studies. In these studies,
the potential for diffusion of tenofovir across an excised human
tissue barrier was evaluated in a Franz cell model using
ectocervical tissue obtained from separate individuals. Both inter-
and intra-patient variability was observed between tenofovir
diffusion profiles obtained from different ectocervical samples
(Figure 3). Regardless, in all experiments, some amount of
tenofovir permeated the excised ectocervical tissue as illustrated
by the detectable levels of drug in the receptor chamber following
exposure to either drug solution or formulated tenofovir gel
product for a 30 min period. However, the amount of tenofovir
present in the receptor chamber at later time points differed
among separate ectocervical samples tested. These data indicate a
potential for variability in the absorption and permeation of
tenofovir following topical administration between individual
ectocervical tissues.
Safety of Tenofovir Gel
Effect of tenofovir gel on vaginal flora. Normal vaginal
flora consists of predominately Lactobacillus species; four different
Lactobacillus species were tested for growth inhibition and toxicity.
Other bacteria associated with bacterial vaginosis (Gardnerella
vaginalis and two Prevotella species) and Neisseria gonorrhoeae were also
tested. Tenofovir (1 mg/ml) was not toxic and did not inhibit the
growth of any of the eight bacterial species tested. The gel
formulation was tested against the same strains of L. cripatus, L.
jenseni, L. vaginalis, and G. vaginalis and there was no loss of viability.
Effect of tenofovir gel on viability of epithelial cell lines
and PBMCs. Dilutions of the tenofovir and vehicle control gels
were cultured with the epithelial cells and PBMCs for 24 hours
and viability was determined as compared to the untreated
control. At a dilution of 1:5, the tenofovir gel showed toxicity
(,60% viability) to the HEC-1-A and Caco-2 epithelial cell lines.
At a dilution of up to 1:10, the tenofovir gel showed toxicity
(,60% viability) to the PBMCs. Subsequent dilutions resolved the
toxicity. Therefore, the minimum nontoxic dilution of the
tenofovir gel was 1:10 (1 mg/ml) for the epithelial cell lines and
1:20 (0.5 mg/ml) for the PBMCs. The vehicle control gel showed
similar results to the epithelial cell lines and PBMCs when diluted
1:10 or 1:20 beyond their original formulations (Figure 4).
When these nontoxic dilutions were added for 2 h per day for 5
days to the epithelial cell lines and viability was assessed, minimal
impact on epithelial cell viability was noted. By day 5, the Caco-2
cells retained their viability when cultured with the tenofovir
(73616%) and vehicle control (82610%) gels. The HEC-1-A cell
line showed better viability when cultured with tenofovir
(118615%) and vehicle control (119623%) gels.
For testing the epithelial monolayer integrity, 1:10 dilutions of
tenofovir and vehicle control gels were added to monolayers of
HEC-1-A and Caco-2 cells and the impact on the monolayer was
measured over 24 h. As a toxicity control, a 1:50 dilution of a 3%
Figure 2. Tenofovir releases from the formulated gel. The in vitro
release data show the release profile of tenofovir from the gel; the slope
of the line represents the release rate of the product. The data shown
represent the mean 6 standard deviation of 13 replicates.
doi:10.1371/journal.pone.0009310.g002
Figure 3. Tenofovir permeates through ectocervical tissue.
Tissue permeability data is shown as the cumulative amount of
tenofovir which permeated through excised human ectocervical tissue
into the receptor chamber of a Franz cell over time. The permeability
data represent five separate tissue donors. Tissue permeability data
illustrate the intra- and inter-patient variability.
doi:10.1371/journal.pone.0009310.g003
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with medium only) for HEC-1-A (upper panel) and Caco-2 (lower
panel) cells varied by no more than 24% in their TER over the
course of the 24 h period (Figure 5). The diluted tenofovir gel
reduced the TER of the HEC-1-A monolayer by 9% (not
significant) and the Caco-2 monolayer by 55% (p=.0026) at 4 h
after application as compared to the control wells. Similar results
were found using the diluted vehicle control gel. However, with
both cell lines, the TER returned to control levels by 24 h after
either product application indicating the disruption of the TER
was transient. Conversely, N9-treated cell monolayers continued
to lose their TER with total loss occurring by 4 h after application.
Effect of tenofovir gel on viability of ectocervical and
colorectal explants. To assess tenofovir and vehicle control
gels impact on tissue viability, ectocervical and colorectal explant
cultures were set-up polarized, in transwells on the day of surgery.
A 1:5 dilution, to ensure even spread over the tissue, of each
product was made in the appropriate medium. The diluted gels
were applied to the epithelial surface of the tissue and remained in
contact for 24 h. The tissues were washed and prepared for the
MTT assay or histology. While no decrease in viability was noted
when using the MTT assay (Figure 6A), which measures
mitochondrial activity, epithelial fracture was noted in 3 of 5
ectocervical and colorectal tissues cultured with tenofovir or
vehicle control gels (Figure 6B). The lamina propria appeared
Figure 4. Viability of peripheral blood mononuclear cells
(PBMCs) and epithelial cell lines after culture with tenofovir
gel. PBMCs or epithelial cell lines (HEC-1-A or Caco-2) were cultured for
24 hours in dilutions of tenofovir or vehicle control gel. Dilutions were
made in the appropriate medium for each cell type. Cell viability was
measured using CellTiter-GloH according to the manufacturer’s
instructions and was calculated as described in the Methods section.
The dilution that was used for subsequent work was the lowest dilution
to result in $60% viability of the cells. The data shown represent the
mean 6 standard deviation of 5 independent experiments performed
in triplicate.
doi:10.1371/journal.pone.0009310.g004
Figure 5. Tenofovir and vehicle control gels transiently
reduced epithelial monolayer integrity. HEC-1-A (upper panel)
and Caco-2 (lower panel) cells were grown in transwell supports until
they formed stable monolayers. A 1:10 dilution of tenofovir or vehicle
control gels were added to the apical chamber at t=0 and resistance
readings were measured at 30 min, 1, 2, 4, 8, and 24 h. As a toxicity
control, a 1:50 dilution (0.6 mg/ml) of nonoxynol-9 (N9) gel was added
to the indicated apical chambers and resistance readings were
measured. The data shown represent the mean 6 standard deviation
of 3 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0009310.g005
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applied to the tissues and showed a 60% reduction in viability
(p=.03) as determined by the MTT assay and stripping of the
epithelium from the lamina propria by histology in all tissues tested
(Figure 6B).
Efficacy of Tenofovir
Efficacy testing of tenofovir gel in PBMCs. Tenofovir is
currently being used as a therapeutic (TDF; VireadH) and has
shown extensive activity against numerous HIV-1 subtypes [16].
However, the formulated tenofovir gel has not been formally
tested for efficacy against HIV-1 subtypes. To fill this gap, the 1:20
dilution of tenofovir or vehicle control gel was mixed with HIV-
1BaL or one of three primary HIV-1 isolates representing two
prominent subtypes in Africa (subtypes A and C) and cultured with
PBMCs. Tenofovir gel reduced HIV-1 infection from 2.7 to 4.7
log10 (p=.03) as compared to the peak p24 levels of the control
cultures (Figure 7). A similar reduction in HIV-1 growth was noted
between tenofovir and vehicle control gel treated cultures.
Tenofovir gel was effective at blocking HIV-1 infection
regardless of subtype.
Efficacy testing of tenofovir gel and tenofovir in explant
cultures. Tenofovir could be used in either a topical or
systemically available dosage form for prevention studies. To
determine whether topical and systemic dosing could be modeled
in explant cultures and if both are effective against HIV-1,
ectocervical and colorectal explant cultures were set-up as
described [29,30]. For topical administration, HIV-1 was mixed
with tenofovir or vehicle control gel and added to the apical side of
the cultures for overnight incubation. To simulate systemic
administration, 1 mg/ml of tenofovir was added to the
basolateral supernatant of the cultures for 15 min and then
HIV-1 was applied to the apical side of the culture for overnight
incubation. Tenofovir, whether applied apically or basolaterally
prevented HIV-1 infection of ectocervical and colorectal explant
cultures. HIV-1 p24gag was reduced by 1.1 log10 (day 10) in
topically-treated and 1.6 log10 (day 10) in basolaterally-treated
ectocervical explants as compared to untreated (HIV-1 only) or
Figure 6. Viability of explant cultures after a 24 hour exposure to tenofovir or vehicle control gels. Ectocervical and colorectal explants
were polarized and tenofovir or vehicle control gels were diluted 1:5 in the appropriate culture medium and applied to the apical surface. A 1:5
dilution of nonoxynol-9 (N9) was applied apically to the explants at the same time as the tenofovir and vehicle control gels as a toxicity control.
Untreated explants were the negative control tissues. The explants were cultured for 24 h, washed five times, and placed in either medium
containing 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) to assess tissue viability by measuring mitochondrial activity (A) or formalin to fix
the tissue for hematoxylin-eosin staining for histology (original magnification 206; bar length 0.05 mm) (B). Explants from five tissue donors were
evaluated for viability after exposure to topical gels. The % viability was determined by dividing the corrected optical density of the treated explant
by the corrected optical density of the control explant. Histology shown is representative of the five tissues evaluated.
doi:10.1371/journal.pone.0009310.g006
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IHC for HIV-1 p24gag positive cells in the untreated (Figure 8A;
upper and lower right panels) and vehicle control-treated tissues
(data not shown) with no detectable IHC positive cells in the
tenofovir-treated tissue. In colorectal tissues (Figure 8B), not only
did tenofovir delivered either apically or basolaterally reduce HIV-
1 p24gag production, by 2.1 log10 (day 18) and 2.0 log10 (day 18)
respectively, but the vehicle control gel reduced HIV-1 p24gag
production by 1.3 log10 (day 21). Despite the reduced p24gag, the
levels increased over time indicating that the explants were not
protected by the vehicle control gel.
With the success of the topical and systemic applications applied
concurrently or just before the addition of HIV-1, we wanted to
know whether delayed application or post-exposure prophylaxis of
drug could prevent explant infection. Tenofovir gel (or vehicle
control gel) (apical) or tenofovir (basolateral) was added to the
appropriate culture either 15 min or 60 min after the addition of
HIV-1 to the explants. The delayed addition of tenofovir protected
the ectocervical (Figure 9A) and colorectal (Figure 9B) explants as
shown by similar log10 reductions of HIV-1 p24gag protein to
those noted above and no detectable infected cells at study
endpoint (immunohistochemistry; ectocervical tissue only). The
vehicle control gel did not reduce HIV-1 infection of the
ectocervical explants, but did delay or reduce HIV-1 infection in
the colorectal explants similar to what was observed for concurrent
administration of gel and virus above.
Discussion
Prevention efforts remain a high priority in the approach to
control the global HIV-1 epidemic. The current microbicides
being developed are specific for HIV-1 and may be more potent
than the first generation, non-specific microbicides. These next
generation microbicides utilize effective therapeutics or specific
anti-HIV-1 targets. Tenofovir gel is the lead candidate being
brought forward in efficacy clinical trials. Also, interest is
increasing in using oral PrEP for HIV-1 prevention. We have
utilized our testing algorithm to evaluate tenofovir gel and the
unformulated drug, tenofovir, for safety and efficacy against HIV-
1. The tenofovir gel has an acidic pH, is shear thinning, and is
hyperosmolar. Tenofovir is reproducibly released from the gel and
is able to permeate into the tissue resulting in the prevention of
HIV-1 infection of the ectocervical and colorectal explant tissues.
When used to simulate systemic dosing (basolateral application),
Figure 7. Efficacy of tenofovir against primary isolates of HIV-1. Peripheral blood mononuclear cells were activated and cultured with HIV-1
(BaL, laboratory-adapted CCR5-using clade B isolate; A103, primary CCR5/CXCR4-using clade A isolate; C012, primary CCR5-using clade C isolate; and
C959, primary CCR5-using clade C isolate) with or without tenofovir or vehicle control gel. After 4 hours, the cultures were washed and fresh medium
was added. Supernatant was collected every 3 to 4 days and stored at -80uC. HIV-1 infection was followed using a p24gag ELISA. The data shown
represent the log10-transformed (pg/mL) 695% confidence interval of 4 (BaL) or 5 (A103, C012, and C959) independent experiments.
doi:10.1371/journal.pone.0009310.g007
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9310Figure 8. Tenofovir applied topically or systemically protect ectocervical and colorectal explants from HIV-1 infection. Tenofovir or
vehicle control gels were mixed with HIV-1BaL and applied to the apical side of ectocervical (A) or colorectal (B) explants. In a separate study to
simulate systemic dosing, tenofovir (1 mg/ml) was added to the basolateral side of the explants 15 min prior to the addition of HIV-1BaL to the apical
side of the tissue. After an overnight incubation, the explants were washed and cultured for 21 days with medium sampled and replaced every 3 to 4
days. HIV-1 replication was monitored in the supernatants using a p24gag ELISA. The data shown represent the median 695% confidence interval of
a minimum of 3 independent tissues performed in duplicate. The wide confidence intervals reflect the p24 variability between tissue donors. For
ectocervical tissue, immunohistochemistry for p24gag positive cells of the day 21 explants was done and representative pictures are shown. Arrows
indicate p24gag positive cells.
doi:10.1371/journal.pone.0009310.g008
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ectocervical and colorectal tissues. Collectively, our findings
suggest that tenofovir, whether used topically (vaginally or rectally)
or systemically, will be effective against HIV-1 infection.
As the development of topical microbicides advances, the
importance of formulation is becoming better appreciated.
General desirable aspects of formulations include safety (e.g.
isosmolar aqueous gels), efficacy, stability, and patient acceptabil-
ity. More specific formulation aspects include optimal retention
time, appropriate drug diffusion, and targeted drug delivery. The
in vitro release data allows us to infer the amount of drug released
by the product. The cumulative release of approximately 670 mM
of tenofovir from the tenofovir gel occurred over the six hours of
the assay. By 15 minutes, 134 mM of tenofovir is released from the
gel which is 67 times greater than the 2 mMI C 50 needed to block
HIV-1 replication in vitro. Four of five tissues studied had
permeability levels above the 2 mMI C 50 by three hours and the
least permeable tissue achieved this level within 4 hours. The
variability observed among these tissues is consistent with the
variable amounts of drug detected in the blood of women in a
clinical trial [19]. Importantly, detectable levels of tenofovir in the
blood (an indication of permeation through the tissue) have been
an indicator of protection in a non-human primate model [17].
The permeability data presented here predict the amount of drug
which will be systemically available upon exposure. However the
evaluation of tenofovir levels in the tissue is also important because
of local HIV-1 target cells. For this reason we are currently
determining the amount of tenofovir that permeates into the
Figure 9. Tenofovir protects ectocervical and colorectal explants up to 60 minutes after HIV-1 exposure. Ectocervical (A) and colorectal
(B) explants were apically treated with HIV-1BaL; 15 min or 60 min later tenofovir or vehicle control gels were applied to the apical surface or tenofovir
(1 mg/ml) was added to the basolateral side of the explants. After incubating overnight, the explants were washed and cultured for 21 days with
medium sampled and replaced every 3 to 4 days. HIV-1 replication was monitored in the supernatants using a p24gag ELISA. The data shown
represent the median 695% confidence interval of a minimum of 3 independent tissues performed in duplicate. The wide confidence intervals reflect
the p24 variability between tissue donors. For ectocervical tissue, immunohistochemistry for p24gag positive cells of the day 21 explants was done
and representative pictures are shown. Arrows indicate p24gag positive cells.
doi:10.1371/journal.pone.0009310.g009
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to protection against HIV-1 infection.
One of the important gaps in the field of microbicide research is
the ability to link pre-clinical safety and efficacy testing to clinical
outcomes for validation of these assays. Frequently products will
show efficacy against HIV-1 in vitro, but result in no benefit or
possibly increased HIV-1 infection during a clinical trial as was the
case for N9 and cellulose sulfate. Because N9 was already available
as an over-the-counter spermicide and early work indicated that it
killed HIV-1 and Neisseria gonorrhoeae [32,33], N9 was clinically
tested as a microbicide. Early clinical trials indicated it was
acceptable and safe [34,35,36,37]. However, two of three efficacy
trials were halted early due to evidence of harm, i.e. increased risk
of HIV-1 infection [38,39,40]. Subsequent studies, including our
own, showed extensive toxicity and damage to epithelial cells and
ectocervical and colorectal explants [28,29,30,41,42,43,44]. Our
bacteriological studies determined most Neisseria gonorrhoeae isolates
were resistant to N9 which explains why the women were not
protected from infection [24]. The use of N9 in our pre-clinical
algorithms is now relegated to the toxicity control. While we have
not tested cellulose sulfate using our pre-clinical algorithm, we
have tested formulated 4% and 0.5% PRO 2000 and Carraguard
gels. We showed that the 4% PRO 2000 gel reduced the
transepithelial resistance in epithelial cells [28] and demonstrated
toxicity in ectocervical and colorectal explant tissues [29,30]. The
0.5% PRO 2000 and vehicle control gels showed no such toxicity.
Moreover, the 0.5% PRO 2000 gel was effective at preventing
HIV-1 infection of PBMCs and explant tissues [28,29,30]. The
2% PRO 2000 arm, but not the 0.5% arm, was halted due to
futility in the MDP301 trial evaluating these PRO 2000 gels for
the prevention of vaginally acquired HIV-1 infection. The HPTN
035 trial showed that 0.5% PRO 2000 reduced HIV-1 infection by
30% as compared to the placebo or condom only arms [11].
Unfortunately, this result for 0.5% PRO 2000/5 gel was not
statistically significant, and was confirmed by the recent release of
results from the MDP301 study [15]. These data are consistent
with the PRO 2000 findings in our pre-clinical algorithm and
others [45]. Even though PRO 2000 appeared effective in in vitro
experiments, semen reduced its efficacy in animal model testing
which may explain the lack of protection in the clinical trials.
While not presented here, we have tested the efficacy of tenofovir
in the presence of semen and have found no reduction of activity
against HIV-1 [46]. Further, we showed that while Carraguard
was quite safe, it was not effective in preventing HIV-1 infection of
PBMCs (especially with primary HIV-1 subtypes), cell-to-cell
transmission of HIV-1, or HIV-1 infection of ectocervical explant
cultures [28,30]. These data are consistent with the clinical trial
findings showing that Carraguard was safe and acceptable to the
women using it, but did not prevent HIV-1 infection [14]. The
parallel results of our pre-clinical testing of formulated products
and those of the clinical trials suggest our algorithm should be
predictive of clinical outcomes.
Our work with tenofovir gel shows a transient reduction in the
transepithelial resistance of the epithelial cells and fracture of the
ectocervical and colorectal epithelium. Because similar observa-
tions were made with the vehicle control gel, these effects can be
attributed to the hyperosmolar nature of the formulation. These
subtle in vitro changes are in contrast to the results from clinical
trials which did not show any safety concerns as determined by self
reports or colposcopic measurements [19,20]. It should be noted
that the placebo used for this study was the vehicle control and not
the Universal Placebo (hydroxyethylcellulose; [47]). Because the
Universal Placebo is isosmolar, its use in clinical trials could show
potential safety concerns of the active gels. The discrepancies
between our findings and those of the clinical studies may be due
to 1) the length of time of exposure to the gel, 2) the dilution of gel
used for the pre-clinical testing, 3) not having a ‘‘no product’’ or
true placebo arm to control for potential genital changes from
background in these populations, 4) subjectivity of self reporting, 5)
timing of sample collection to capture attributable changes, and/
or 6) sensitivity of colposcopic testing to detect the subtle, transient
changes in the epithelium. For points 1 and 2, there is little
published data regarding how long a gel is retained in the vagina
or rectum and how mucosal fluids dilute the gel in situ. We utilized
a 1:5 dilution of the gels for testing, because these gels are viscous
and hard to manipulate for culture conditions. For point 3, the use
of the Universal Placebo gel may obviate the need for a ‘‘no
product’’ arm. It is important to note for points 4 and 5, daily use
of vaginally or rectally applied N9 by volunteers was well tolerated
[37,48,49] and for point 6, the timing of when colposcopy or other
testing is done in relationship to the last product dose was
important [44,50]. A recent colposcopy study showed that there
was no increase in genital lesions in women using various N9
formulations compared to condom only users [51]. However, N9
was used coitally and colposcopy was not standardized after
product use. Phillips et al. [44,50] evaluated a N9-containing gel
applied rectally by taking rectal lavages and biopsies at 15 min
through 12 h post dose. Denudation of the epithelium was found
at 15 min with completely normal epithelium by 12 h. These data
illustrate that variability can be found during clinical studies and
interpretation of the data is dependent on when samples are taken.
While explant testing performed for this study regarding N9
toxicity findings was consistent with previous studies [29,30],
explant cultures have limitations that include 1) lack of hormone
modulation (ectocervical tissue), 2) no recruitment of immune cells,
and 3) inability to regenerate/repair. While epithelial fracture was
observed in the majority of ectocervical and colorectal explants
after tenofovir gel application, no damage was observed in the
lamina propria. The inability of the explants to repair makes this
system more sensitive to potential changes by topical formulations
than in vivo use.
Unformulated tenofovir has previously been evaluated in rectal
explants for efficacy [52,53]. For this system, tissue pieces were
placed unpolarized into tissue culture wells with varying
concentrations of tenofovir and a standard amount of HIV-1.
Under these conditions, tenofovir was shown to be effective against
HIV-1 infection. However, these data are hard to extrapolate to
the gel that will be used in clinical trails. Using our more stringent
model of polarizing the tissue, topical application of formulated
tenofovir gel was protective against HIV-1. Further, our polarized
model also allows us to simulate systemic dosing of drug by
applying tenofovir (1 mg/ml) to the basolateral side of the tissue
(lamina propria) and HIV-1 to the apical side of the tissue
(epithelium). Using this system, tenofovir applied basolaterally was
effective at preventing HIV-1 infection of the explants. Application
of tenofovir gel apically or tenofovir basolaterally 15 to 60 minutes
after HIV-1 challenge was also protective. The efficacy of
tenofovir when used clinically is still not known, but the data
provided here suggest that tenofovir will be effective topically or
systemically to prevent the sexual transmission of HIV-1.
Pre-clinical testing of microbicide products has greatly advanced
this past decade. Innovative systems are being used and developed
to recapitulate human exposure as best we can. While we still do
not know the intricacies of how HIV-1 is transmitted, compre-
hensive pre-clinical algorithms such as those described here
provide important basic science information while supplementing
and guiding animal and human studies. Vaginal and rectal
exposure models in non-human primates have shown the
Tenofovir Pre-Clinical Testing
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protecting the majority of the animals challenged with SHIV
[17,18,54]. The inclusion of biopsies from early clinical studies to
challenge with HIV-1 ex vivo may allow us to more accurately
determine the efficacy of the drug in subsequent clinical trials. This
concept is supported by a recent study using a non-nucleoside
reverse transcriptase inhibitor, UC781, applied rectally with
biopsies taken at defined time points after gel application. The
biopsies taken 30 minutes after gel application were protected
from HIV-1 infection [55]. The data presented here suggest that a
thorough pre-clinical evaluation of the formulated microbicide is
needed as effective candidates are identified and before they move
into clinical trials.
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